$MAIA reported an 88% disease control rate in its Phase 2 THIO-101 trial of ateganosine followed by cemiplimab in third-line NSCLC. A new @NobleCapMkts report highlights the updated data and Phase 3 THIO-104 progress.
Read via @channelchek: https://t.co/UPId9TP4gN
Today, MAIA Biotechnology ($MAIA) reported an 88% disease control rate across Parts A, B and C of its Phase 2 THIO-101 trial in third-line NSCLC, compared with 25%-35% for standard third-line chemotherapy.
Read more: https://t.co/TbHe0mglYp
$MAIA’s clinical progress is highlighted in @diamondequities’s November update, noting completed THIO-101 Part C enrollment, 150 patients treated, and momentum toward a 2027 Phase 3 interim analysis.
Access the report: https://t.co/z7bBwuuAvO
$MAIA has achieved patient enrollment milestones in its Phase 2 and pivotal Phase 3 NSCLC trials. Part C of THIO-101 is fully enrolled, while THIO-104 has reached 65% of its 2026 enrollment target.
Read more: https://t.co/SsRSQJ4x6j
$MAIA has received regulatory approval in Spain and Portugal to begin screening patients in its pivotal Phase 3 THIO-104 trial evaluating ateganosine in NSCLC. To date, THIO-104 has enrolled 60 NSCLC patients across existing sites.
Read: https://t.co/KHfdM90HgY
$MAIA has reached 65 randomized patients in its pivotal Phase 3 THIO-104 trial evaluating ateganosine as a third-line treatment for advanced NSCLC.
The trial currently has 38 activated sites across six countries.
Read more: https://t.co/qAsItdXQiy
$MAIA has dosed the first U.S. patient in its Phase 2 THIO-101 expansion trial, evaluating ateganosine in third-line NSCLC. The U.S. expansion is supported by a $2.3M NIH grant and the study has now enrolled patients across four continents.
Read more: https://t.co/kWtFWu1iou
$MAIA presented two studies at #IRT2026 covering novel divalent cancer RedOx-activatable prodrugs and dual-pharmacophore dinucleotide prodrugs. Preclinical testing identified molecular features associated with increased antitumor activity.
Read more: https://t.co/t1eIOhpgNo
We’re proud to share that MAIA Biotechnology has been nominated for the 2026 Prix Galien USA Award in the Best Startup category.
Thank you to @GalienFdn for this recognition. We look forward to the awards ceremony this October.
https://t.co/AsC8AgHq99 $MAIA
@GalienFdn We’re honored to be nominated for the 2026 Prix Galien USA Award in the Best Startup category and to be recognized alongside such an impressive group of innovators. Thank you, The Galien Foundation. We look forward to celebrating with everyone in October.
Thank you @Benzinga for highlighting MAIA’s latest Phase 2 THIO-101 clinical update - including a 90.5% disease control rate in third-line NSCLC patients receiving ateganosine followed by cemiplimab.
https://t.co/U8GDTEuxId $MAIA
From telomere biology to clinical development, MAIA Chairman & CEO Dr. Vlad Vitoc explains how ateganosine, a first-in-class investigational telomere-targeting agent, is being developed as a treatment for third-line NSCLC.
Watch: https://t.co/muF0OYrp9g $MAIA @SullyOnTheAir
Initial efficacy observations from Part C of the Phase 2 THIO-101 trial remained consistent with previously reported THIO-101 clinical activity, despite evaluating a more heavily pre-treated third-line NSCLC patient population.
Learn more: https://t.co/WHAfoHyJRy $MAIA
MAIA Biotechnology reported positive initial efficacy data from Part C of its Phase 2 THIO-101 trial, including a 90.5% disease control rate in third-line NSCLC patients receiving ateganosine followed by cemiplimab.
Learn more: https://t.co/WHAfoHyJRy $MAIA
From enrollment momentum to clinical site expansion, June brought several notable milestones for MAIA Biotechnology's clinical programs evaluating ateganosine in advanced NSCLC.
Discover @Channelchek's recap here: https://t.co/pBI9IM458s $MAIA
MAIA Biotechnology completed international enrollment in Part C of its Phase 2 THIO-101 expansion trial evaluating ateganosine in advanced NSCLC patients receiving third-line therapy.
Patient screening continues at three U.S. clinical sites.
Learn more: https://t.co/x3EsAAfP0C
The THIO-101 expansion trial continues to evaluate ateganosine as a third-line treatment in patients with advanced NSCLC who have previously received checkpoint inhibitors and chemotherapy.
Read the latest update: https://t.co/7qNvfFMX7Z $MAIA
MAIA has opened enrollment at @winshipatemory, the third U.S. clinical site participating in the Phase 2 THIO-101 expansion trial evaluating ateganosine as a third-line treatment for advanced NSCLC.
Learn more: https://t.co/jY9FOUI1f7 $MAIA
As MAIA advances its pivotal Phase 3 THIO-104 trial, the study continues to evaluate ateganosine as a potential third-line treatment option for patients with advanced NSCLC who have progressed following prior therapies.
Learn more about the trial: https://t.co/Yo2P7KhP8t $MAIA